Adalyon’s CEO, Ulrik Zeuthen, notes that speech-based biomarkers can be used across several applications to optimise trial ...
Atea showcased its Phase III HCV programme at JPM, positioning the regimen for test-and-treat adoption in 1,800 patients.
Intellia Therapeutics CEO John Leonard explained the circumstances of the patient death at the J.P. Morgan Healthcare ...
Axsome Therapeutics has initiated the FORWARD Phase III trial evaluating AXS-14 for the management of fibromyalgia, with the ...
Sanofi's amlitelimab has shown promise in the Phase III COAST 1 trial, but data from the COAST 2 study is yet to be announced ...
The FDA and EMA's joint guidance was created to ensure the pharmaceutical industry employs best practices when using AI in ...
Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...
In a paper published in Nature Scientific Reports, the UK Biobank was used to better understand how the risk of stroke is ...
An independent data monitoring committee has advised Akeso to submit a sNDA to the NMPA for cadonilimab’s approval in gastric ...
Tanabe Pharma is one of two companies developing a treatment for EPP and XLP. Image credit: Guenter Albers / Shutterstock.com Tanabe Pharma America’s oral melanocortin-1 receptor (MC1R) agonist has ...
The integration involving ERAs represents the most comprehensive synthesis to date on ERA efficacy and safety in CKD populations. Credit: NMK-Studio via Shutterstock.com. A recent research study, ...
D3 Bio will begin a Phase I trial for patients with advanced solid tumours harbouring KRAS G12D mutations. Credit: Bohbeh creations / Shutterstock.com. D3 Bio has received the US Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback